<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02781935</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-1527-GITCG-IG</org_study_id>
    <nct_id>NCT02781935</nct_id>
  </id_info>
  <brief_title>Diffusion-Weighted MRI for Liver Metastasis</brief_title>
  <acronym>DREAM</acronym>
  <official_title>Diffusion-Weighted Magnetic Resonance Imaging Assessment of Liver Metastasis to Improve Surgical Planning</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Japan Clinical Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Society of Surgical Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The DREAM study will assess the diagnostic accuracy of diffusion-weighted MRI in combination
      with other imaging modalities (multiparametric MRI and CT Scan) in determining the true
      status of disappearing liver metastasis (DLM) detected after conversion systemic therapy for
      unresectable or borderline resectable colorectal liver metastasis (CRLM).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The advancements of systemic and local therapies for complex CRLM have led to the increased
      incidence of DLMs. It is hypothesized that DW-MRI imaging could distinguish between a
      metastasis not completely sterilized by conversion therapy and a sterilized scar (non-viable
      tumor). If this can be demonstrated, the use of DW-MRI could make a significant impact on the
      surgical decision making process by providing surgeons a more reliable guide to decide
      whether to leave behind or to resect/ablate a site of DLM. Most importantly, this surgical
      choice can also have a significant impact on patient outcomes as it may impact the risk of
      local recurrence and the need for re-operation.The possibility of improving surgical
      management of complex CRLM is foreseen if the benefit of observing or resecting small
      residual metastases and DLMs is clarified through a multi-center and international
      prospective study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Negative Predictive Value (NPV) of the diagnostic imaging (DW-MRI)</measure>
    <time_frame>2 years after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>NPV of diagnostic imaging among the group of resected confirmed DLMs</measure>
    <time_frame>2 years after the surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NPV of diagnostic imaging in the group of confirmed DLMs that were left in place</measure>
    <time_frame>2 years after ther surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NPV of DW-MRI in the group of cDLMs diagnosed by central imaging review</measure>
    <time_frame>2 years after the surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between different types of morphologic and ADC changes and TRG to the type of conversion therapy</measure>
    <time_frame>2 years after the surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between findings on DW-MRI to histopathology, recurrence rate, complication rates, PFS and OS</measure>
    <time_frame>2 years after initial surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term outcomes of patients who underwent surgery in terms of: - recurrence rates for 2 years after surgery - progression free survival for 2 years after surgery - overall survival for 2 years after surgery</measure>
    <time_frame>2 years after initial surgery</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Colon Cancer Liver Metastasis</condition>
  <condition>Malignant Neoplasm of Rectum Metastatic to Liver</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>DW-MRI</intervention_name>
    <description>DW-MRI combined with Contrast Enhanced MRI will be used to confirm the status of disappearing liver metastasis prior to surgery and will be compared to findings from either histopathology of resected lesions (Rubbia-Brandt Classification of Tumor regression grading) or follow-up imaging of lesions left behind (either CT scan or MRI) after surgery. MRI will be used during the follow-up period to confirm recurrences from a previous site of DLM.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Primary tumor histologically proven as colorectal adenocarcinoma, colorectal mucinous
        adenocarcinoma, colorectal signet ring cell carcinoma or colorectal adenosquamous carcinoma

        Unresectable or borderline resectable liver metastases at the time of diagnosis for liver
        metastases. Both synchronous and metachronous metastases are allowed

        Age ≥18 years old

        With informed consent
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for Eligibility:

          1. Contrast-enhanced thorax, abdomen and pelvic CT scan (with at least portal venous
             phase for the liver) at diagnosis and right before surgery are available

          2. Multiparametric MRI at baseline and right before surgery are available (T1/T2, DW-MRI
             and contrast enhanced MRI).

          3. WHO performance status of 0 or 1

          4. Previous treatments (chemotherapy, surgery) for primary, liver and extra-hepatic
             metastases are allowed.

          5. No other malignancies in the 3 years prior to study entry with the exception of
             surgically cured carcinoma in situ of the cervix, in situ breast cancer, incidental
             finding of stage T1a or T1b prostate cancer gleason score ≤ 6, and basal/squamous cell
             carcinoma of the skin

          6. Absence of any psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule; those
             conditions should be discussed with the patient before registration in the study

        Criteria for Enrollment

          1. Conversion therapy is either being given or completed

          2. Patient is suitable for hepatic resection based on the assessment of MDT composed of
             at least an expert liver/colorectal surgeon, Gastrointestinal (GI) radiologist and
             oncologist prior to any liver surgery

          3. Hepatic resection is scheduled to take place within 8 weeks of latest imaging

        Exclusion Criteria:

          1. Contraindications to any contrast agents for CT and MRI or MRI procedure

          2. Pregnancy

          3. Significant comorbidity that will preclude either conversion therapy or surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Serge Evrard</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Bergonie, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefanie Schrauwen</last_name>
    <phone>003227741524</phone>
    <email>stefanie.schrauwen@eortc.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hyunseon Kang, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Der Wiener Krankenanstaltenverbund - Krankenanstalt Rudolfstiftung</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thomas Gruenberger, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Roberto Troisi, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Serge Evrard, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michel Rivoire, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michel Ducreux, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chiba Cancer Center</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nobuhiro Takiguchi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gifu University Hospital</name>
      <address>
        <city>Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kazuhiro Yoshida</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hiroshima Prefectural Hospital</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Satoshi Ikeda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Niigata Prefectural Cancer Center Hospital</name>
      <address>
        <city>Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yasumasa Takii</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osaka Medical Center for Cancer and Cardiovascular Diseases</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Masayuki Ohue</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gunma Cancer Center</name>
      <address>
        <city>Ota-City</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hitoshi Ojima</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jichi Medical University Saitama Medical Center</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yasuyuki Miyakura</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yusuke Kinugasa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yoji Kishi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical and Dental University</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Uetake Hiroyuki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yamagata Prefectural Central Hospital</name>
      <address>
        <city>Yamagata</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Toshihiko Sato</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cancer Center</name>
      <address>
        <city>Yokohama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 1</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Wojciech Polkowsk, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie Memorial Cancer Centre</name>
      <address>
        <city>Warsaw</city>
        <zip>02 781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lucjan Wyrwicz, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Japan</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2016</study_first_submitted>
  <study_first_submitted_qc>May 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2016</study_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unresectable colorectal liver metastasis</keyword>
  <keyword>diffusion weighted MRI</keyword>
  <keyword>disappearing liver metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

